FDA Approves Pacritinib for Myelofibrosis

On Monday, February 28, 2022, the U.S. Food and Drug Administration (FDA) approved pacritinib for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 10⁹/L.

Read CTI Biopharma's announcement.

Posted 3/1/2022